Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Mar 17, 2011

Premium

Title: Bioinformatically Detectable Group of Novel Regulatory Oligonucleotides Associated with Alzheimer's Disease and Uses Thereof

Patent Number: 7,906,326

Filed: Feb. 16, 2004

Lead Inventor: Isaac Bentwich, Rosetta Genomics

The invention relates to a group of novel oligonucleotides referred to as genomic address messenger oligonucleotides, and a group of novel operon-like polynucleotides called genomic record polynucleotides, the patent's abstract states. “GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various diseases.”

The application, the abstract states, claims “nucleic acid molecules ... encoding 1,708 GAM oligonucleotides and 246 GR polynucleotides ... as are vectors and probes both comprising the nucleic acid molecules. [Also claimed are] methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.”


Title: Group of Nucleic Acid Fragments for Prevention of HIV Infections or AIDS and the Usage Thereof

Patent Number: 7,906,641

Filed: Dec. 16, 2003

Lead Inventor: Zhiwen Zhou, Beijing Solobio Genetechnology

“The invention provides a group of nucleic acid fragments ... for [the] prevention of HIV infection or AIDS, and the usage thereof,” the patent's abstract states. “In the invention, a series of RNA fragments, which are highly homogenous to all the published HIV gene sequences, were obtained … [and the] double-stranded RNA derived from these fragments can effectively inhibit the expression of the HIV genes. The RNA transcribed by [a] plasmid also can suppress the expression of the HIV in the cell. After the adenovirus or associated virus, which carry DNA corresponding [to the] above RNA, infect the cell, the transcription dsRNA can inhibit the expression of the HIV genes.”


Title: Peptide Dicer-Substrate Agents and Methods for Their Specific Inhibition of Gene Expression

Application Number: 20110059187

Filed: June 3, 2010

Lead Inventor: Sujit Basu, Dicerna Pharmaceuticals

“This invention relates to compounds, compositions, and methods useful for reducing a target RNA and protein levels via use of Dicer-substrate siRNA-peptide conjugates,” the patent application's abstract states.


Title: Method for Expression of Small RNA Molecules Within a Cell

Application Number: 20110059531

Filed: June 7, 2010

Lead Inventor: Carlos Lois-Caballe, California Institute of Technology

“The invention provides methods and compositions for the expression of small RNA molecules within a cell using a lentiviral vector,” the patent application's abstract states. “The methods can be used to express double-stranded RNA complexes … [and] small interfering RNA can be expressed using the methods of the invention within a cell, which are capable of down regulating the expression of a target gene through RNA interference. A variety of cells can be treated according to the methods of the invention including embryos [and] embryogenic stem cells, allowing for the generation of transgenic animals or animals constituted partly by the transduced cells that have a specific gene or a group of genes down regulated.”


Title: Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus

Application Number: 20110060031

Filed: May 27, 2010

Lead Inventor: Sina Bavari, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the Ebola virus,” according to the patent application's abstract.


Title: Lipid-Encapsulating Interfering RNA

Application Number: 20110060032

Filed: Aug. 6, 2010

Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

The invention comprises “lipid-based formulations for delivering … nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations,” according to the patent application's abstract.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.